Search - tctmd.com

Displaying 1 - 20 of 54

Sort: Relevancy | Date

Presentation TCT 2025

DAPT -Shock-AMI with use of Cangrelor

Presenter: Babar Basir

October 28, 2025

Presentation TCT 2024

TCT 299: Cangrelor Use in Acute Myocardial Infarction Patients Awaiting Coronary Artery Bypass Grafting

Presenter: Jennifer Rymer

October 29, 2024

Presentation TCT 2024

TCT 784: Gender Disparities in Cangrelor Outcomes for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Presenter: Waiel Abusnina

October 29, 2024

Presentation TCT 2024

TCT 174: High Bleeding Risk and Outcomes in Acute Coronary Syndrome After Percutaneous Coronary Intervention With Versus Without Cangrelor

Presenter: Patrick Creechan

October 28, 2024

Presentation TCT 2024

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

Presenter: Angelo Oliva

October 27, 2024

Presentation TCT 2024

TCT 1: Differential Outcomes in ST-Elevation and Non-ST Elevation Myocardial Infarction Outcomes After Percutaneous Coronary Intervention With Versus Without Cangrelor

Presenter: Andrew Hill

October 27, 2024

Presentation TCT 2024

TCT 1351: Cangrelor in a Challenging Scenario of Concomitant Ischemic Stroke, Pulmonary Embolism and STEMI

Presenter: Federico Oliveri

October 27, 2024

Presentation TCT 2024

TCT 238: Safety and Efficacy of Cangrelor: A Multicenter Nationwide Registry ARECA (Austrian Registry for Cangrelor Application)

Presenter: Guy Friedrich

October 27, 2024

Presentation TCT 2024

TCT 236: Bailout Use of Cangrelor During Percutaneous Coronary Intervention and Associated Inpatient Outcomes

Presenter: Abhishek Chaturvedi

October 27, 2024

Presentation TCT 2023

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Presenter: Michael Savage

October 25, 2023

Presentation TCT 2023

Cangrelor Reduces Procedural Complications and Should Be the Default Strategy

Presenter: Jennifer Rymer

October 25, 2023

News Conference News TCT 2020

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

Shelley Wood

October 14, 2020

News Conference News TCT 2020

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

L.A. McKeown

October 14, 2020

Presentation TCT 2020

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Presenter: Jennifer Rymer

October 14, 2020

Presentation TCT 2018

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Presenter: John A. Bittl, C. Michael Gibson, Deepak L. Bhatt

September 23, 2018

Presentation TCT 2017

Switching to and From Cangrelor: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Why I Use Cangrelor for Primary PCI in STEMI!

Presenter: Michael S. Lee, Dirk Sibbing, Dmitriy N. Feldman

October 30, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Debate: Making the Case for Very Limited Use of Cangrelor!

Presenter: Deepak L. Bhatt, Christian W. Hamm, Sorin J. Brener

October 30, 2016

Advertisement

DAPT -Shock-AMI with use of Cangrelor

TCT 299: Cangrelor Use in Acute Myocardial Infarction Patients Awaiting Coronary Artery Bypass Grafting

TCT 784: Gender Disparities in Cangrelor Outcomes for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

TCT 174: High Bleeding Risk and Outcomes in Acute Coronary Syndrome After Percutaneous Coronary Intervention With Versus Without Cangrelor

TCT 227: Timing and Indications for Cangrelor Use and Transition Modalities to Oral P2Y12 Inhibitors in Patients Undergoing PCI: Insights From the SMILE Study

TCT 1: Differential Outcomes in ST-Elevation and Non-ST Elevation Myocardial Infarction Outcomes After Percutaneous Coronary Intervention With Versus Without Cangrelor

TCT 1351: Cangrelor in a Challenging Scenario of Concomitant Ischemic Stroke, Pulmonary Embolism and STEMI

TCT 238: Safety and Efficacy of Cangrelor: A Multicenter Nationwide Registry ARECA (Austrian Registry for Cangrelor Application)

TCT 236: Bailout Use of Cangrelor During Percutaneous Coronary Intervention and Associated Inpatient Outcomes

I Don’t Need Cangrelor With Available Potent Oral P2Y12 or 2b3a Inhibitors

Cangrelor Reduces Procedural Complications and Should Be the Default Strategy

Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate

No Reperfusion Benefit From Crushed Prasugrel Prior to PCI: COMPARE CRUSH

TCT 065: Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Early Results From the Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes (CAMEO) Registry

Utility of Cangrelor During PCI and Bridging Who Benefits Most?

Switching to and From Cangrelor: When and How?

Why I Use Cangrelor for Primary PCI in STEMI!

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Debate: Making the Case for Very Limited Use of Cangrelor!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content